These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 35417530

  • 1. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
    Nguyen TTT, Shang E, Schiffgens S, Torrini C, Shu C, Akman HO, Prabhu VV, Allen JE, Westhoff MA, Karpel-Massler G, Siegelin MD.
    Clin Cancer Res; 2022 May 02; 28(9):1881-1895. PubMed ID: 35417530
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems.
    Nguyen TTT, Zhang Y, Shang E, Shu C, Quinzii CM, Westhoff MA, Karpel-Massler G, Siegelin MD.
    Cells; 2020 Jul 10; 9(7):. PubMed ID: 32664214
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
    Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TTT, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD.
    Clin Cancer Res; 2018 Nov 01; 24(21):5392-5406. PubMed ID: 30037819
    [Abstract] [Full Text] [Related]

  • 5. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models.
    Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, Bianchetti E, Mela A, Humala N, Mahajan A, Harmanci AO, Lei Z, Maienschein-Cline M, Quinzii CM, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD.
    J Clin Invest; 2020 Jul 01; 130(7):3699-3716. PubMed ID: 32315286
    [Abstract] [Full Text] [Related]

  • 6. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R, Zhou L, Chang WI, Zhang Y, Sharma A, Prabhu VV, Tapinos N, Lulla RR, El-Deiry WS.
    Am J Cancer Res; 2021 Jul 01; 11(9):4607-4623. PubMed ID: 34659909
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
    Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M.
    Cancer Cell; 2019 May 13; 35(5):721-737.e9. PubMed ID: 31056398
    [Abstract] [Full Text] [Related]

  • 10. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    Tung B, Ma D, Wang S, Oyinlade O, Laterra J, Ying M, Lv SQ, Wei S, Xia S.
    BMC Cancer; 2018 Oct 22; 18(1):1025. PubMed ID: 30348136
    [Abstract] [Full Text] [Related]

  • 11. ONC206 targeting ClpP induces mitochondrial dysfunction and protective autophagy in hepatocellular carcinoma cells.
    Cao J, Cao F, Wang C, Jiao Z, You Y, Wang X, Zhao W.
    Neoplasia; 2024 Sep 22; 55():101015. PubMed ID: 38944913
    [Abstract] [Full Text] [Related]

  • 12. Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.
    Jacques S, van der Sloot AM, C Huard C, Coulombe-Huntington J, Tsao S, Tollis S, Bertomeu T, Culp EJ, Pallant D, Cook MA, Bonneil E, Thibault P, Wright GD, Tyers M.
    Genetics; 2020 Apr 22; 214(4):1103-1120. PubMed ID: 32094149
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
    Zhang Y, Ishida CT, Shu C, Kleiner G, Sanchez-Quintero MJ, Bianchetti E, Quinzii CM, Westhoff MA, Karpel-Massler G, Siegelin MD.
    Sci Rep; 2018 May 09; 8(1):7373. PubMed ID: 29743557
    [Abstract] [Full Text] [Related]

  • 14. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E, Zhang Y, Shu C, Ishida CT, Bianchetti E, Westhoff MA, Karpel-Massler G, Siegelin MD.
    Sci Rep; 2018 Oct 18; 8(1):15383. PubMed ID: 30337641
    [Abstract] [Full Text] [Related]

  • 15. Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
    Fennell EMJ, Aponte-Collazo LJ, Wynn JD, Drizyte-Miller K, Leung E, Greer YE, Graves PR, Iwanowicz AA, Ashamalla H, Holmuhamedov E, Lang H, Karanewsky DS, Der CJ, Houry WA, Lipkowitz S, Iwanowicz EJ, Graves LM.
    Pharmacol Res Perspect; 2022 Aug 18; 10(4):e00993. PubMed ID: 35929764
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
    Pinkerneil M, Hoffmann MJ, Deenen R, Köhrer K, Arent T, Schulz WA, Niegisch G.
    Mol Cancer Ther; 2016 Feb 18; 15(2):299-312. PubMed ID: 26772204
    [Abstract] [Full Text] [Related]

  • 17. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
    Grinshtein N, Rioseco CC, Marcellus R, Uehling D, Aman A, Lun X, Muto O, Podmore L, Lever J, Shen Y, Blough MD, Cairncross GJ, Robbins SM, Jones SJ, Marra MA, Al-Awar R, Senger DL, Kaplan DR.
    Oncotarget; 2016 Sep 13; 7(37):59360-59376. PubMed ID: 27449082
    [Abstract] [Full Text] [Related]

  • 18. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA.
    Clin Cancer Res; 2015 May 15; 21(10):2348-58. PubMed ID: 25688158
    [Abstract] [Full Text] [Related]

  • 19. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
    Nepali K, Hsu TI, Hsieh CM, Lo WL, Lai MJ, Hsu KC, Lin TE, Chuang JY, Liou JP.
    Eur J Med Chem; 2021 May 05; 217():113338. PubMed ID: 33744690
    [Abstract] [Full Text] [Related]

  • 20. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
    Meng W, Wang B, Mao W, Wang J, Zhao Y, Li Q, Zhang C, Ma J.
    Nagoya J Med Sci; 2019 Feb 05; 81(1):93-102. PubMed ID: 30962658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.